Regulatory approval
Published by the Health Canada. Approved
LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | BRCA1 oncogenic variants | Prostate Adenocarcinoma | Olaparib | |
| HC (1) | BRCA1 pathogenic variants | Prostate Adenocarcinoma | Olaparib | |
| HC (1) | BRCA2 oncogenic variants | Prostate Adenocarcinoma | Olaparib | |
| HC (1) | BRCA2 pathogenic variants | Prostate Adenocarcinoma | Olaparib | |
| HC (1) | ATM pathogenic variants | Prostate Adenocarcinoma | Olaparib | |
| HC (1) | ATM oncogenic variants | Prostate Adenocarcinoma | Olaparib |